The Incidence of Malignant Tumors of the Female Reproductive System in St. Petersburg

Introduction: Malignant neoplasms remain a serious sociomedical problem that requires solutions to health care optimization. In the overall structure of cancer incidence in the female population in 2018, uterine and cervical cancer ranked third (8.0 %) and fifth (5.2 %), respectively.

Objective: To determine the main trends in the incidence of gynecologic cancers in Saint Petersburg, Russian Federation, and to monitor achievement of the targets of the Fight against Cancer Program.

Materials and methods: To assess the prevalence and the structure of the incidence of malignant neoplasms of the female reproductive system, a comprehensive methodology was developed, which included the analysis of statistical reporting forms officially approved by the Ministry of Health of the Russian Federation for 2010–2020.

Results: The prevalence of gynecologic cancers showed a steady rise. In 2011–2019, the incidence rates of cervical, uterine and ovarian cancer in St. Petersburg increased by 6.9 %, 18.2 %, and 18.5 %, respectively. The proportion of cases of the uterine body cancer was the largest (43.6 %), followed by ovarian (28.7 %) and cervical cancer (22.5 %). The shares of malignant neoplasms of other sites, including vulva, vagina and placenta, were much lower and equaled 3.9 %, 1.2 %, and 0.1 %, respectively. At the same time, the percentage of followed-up patients with stages I and II uterine cancer had grown from 74.4 % in 2011 to 79.4 % in 2020 (t = 4.9, p < 0.05) and of those with stages I and II ovarian cancer – from 32.2 % to 35.5 % (t = 3.7, p < 0.05). The one-year gynecologic cancer mortality rate in St. Petersburg decreased significantly, from 25.8 % to 20.1 % (t = 4.0, p < 0.05), while the five-year survival in 2011–2020, on the contrary, increased from 52.3 % to 57.9 %.

Conclusions: Malignant tumors of the female reproductive system rank first in the structure of the annual cancer incidence. Every sixth (15.1 %) incident cancer is a gynecologic neoplasm. In 2011–2019, rising incidence rates were observed for the most common female genital tract tumors, including cervical, uterine, and ovarian cancer. It is of great concern that not all monitored indicators approved by the Fight against Cancer Program are being properly implemented in St. Petersburg.

1. Naygovsina NB, Filatov VB, Patrushev MA. The improvement of medical care of patients with oncologic diseases within the framework of the Priority National Project „Health”. Problemy Sotsial’noy Gigieny, Zdravookhraneniya i Istorii Meditsiny. 2020;28(2):216–221. (In Russ.) doi: 10.32687/0869-866X-2020-28-2-216- 221

2. Kulakova NN, Kolodina AA. Problems and prospects of social policy (for example helping oncology patients). Liberal’no-Demokraticheskie Tsennosti. 2018;2(1):4. (In Russ.)

3. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin. 2016;66(1):43–73. doi: 10.3322/caac.21319

4. Sibeoni J, Picard C, Orri M, et al. Patients’ quality of life during active cancer treatment: a qualitative study. BMC Cancer. 2018;18(1):951. doi: 10.1186/ s12885-018-4868-6

5. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. J Clin Oncol. 2016;34(6):611–635. doi: 10.1200/ JCO.2015.64.3809

6. Aksel EM, Vinogradova NN. Statistics of malignant neoplasms of female reproductive organs. Onkoginecologiya. 2018;(3(27)):64–78. (In Russ.) doi: 10.52313/22278710_2018_3_64

7. Vlasina AYu, Solopova AG, Ivanov EA. Anticancer diet, or principles of rational nutrition in gynecological cancer patients during rehabilitation. Vrach. 2020;31(4):3–7. (In Russ.) doi: 10.29296/25877305- 2020-04-01

8. Karol EV, Kozlov SI, Popova NV, Kuznetsova YuI, Belavina EA, Maltseva MA. Dynamics of primary disability indicators of the adult population of Saint Petersburg over the period of 2015–2019. Mediko-Sotsial’nye Problemy Invalidnosti. 2020;(3):101–105. (In Russ.)

9. Mirdadaeva DD, Suparkhanova DR, Tursunov HNK. [Quality of life after treatment for cervical cancer.] Nauka i Obrazovanie Segodnya. 2017;(4(15)):93–96. (In Russ.)

10. Oleynikova IN, Gens GP, Sirota NA, Shikina VE, Kirkin VV. Distress, quality of life and neoangiogenesis in patients with ovarian cancer. Onkoginekologiya. 2019;(3(31)):61–67. (In Russ.) doi: 10.52313/22278710_2019_3_61

11. Chernichenko II, Hadzhieva JeD, Geraschenko JaL, Lonshakova AS. Complex diagnostics of diseases of mammary glands and pelvic organs as secondary prevention of cancer. Issledovaniya i Praktika v Meditsine. 2018;5(S1):93–94. (In Russ.) doi: 10.17709/2409- 2231-2018-5-S1

12. Konovalov OE, Zudin AB, Vasilieva TP. Making management decisions on oncopathology prevention based on monitoring of disease dynamics and trends. Problemy Sotsial’noy Gigieny, Zdravookhraneniya i Istorii Meditsiny. 2020;28(S):754–757. (In Russ.) doi: 10.32687/0869-866X-2020-28-s1-754-757

13. Bochkova AG, Domozhirova AS, Aksenova IA, Novikova TS. [Evaluation of the effectiveness of technologies for early detection of malignant neoplasms of visual localization of female genital organs in the territory of the Chelyabinsk region (on the example of the work of examination rooms).] Zlokachestvennye Opukholi. 2018;8(3S1):280–281. (In Russ.)

14. Madyanova VV, Kakorina EP, Klokova TA. The characteristics of mortality of population older that able-bodied age in the Russian Federation in 2012–2018. Problemy Sotsial’noy Gigieny, Zdravookhraneniya i Istorii Meditsiny. 2020;28(4):523–528. (In Russ.) doi: 10.32687/0869-866X-2020-28-4-523-528

15. Konovalov OE, Vasiliev MD, Chumakov AS, Malakhova AR. Incidence of malignant nominations in the population of the Moscow region, the Central Federal District and the Russian Federation. Byulleten’ Natsional’nogo Nauchno-Issledovatel’skogo Instituta Obshchestvennogo Zdorov’ya Imeni N.A. Semashko. 2020;(4):24–33. (In Russ.) doi: 10.25742/NRIPH.2020.04.003

16. Sciotto F, Py C, Tsantoulis P. [Follow-up of the long-term cancer survivor]. Rev Med Suisse. 2017;13(563):1044–1048. (In French.)

17. Jatoi I, Anderson WF, Miller AB, Brawley OW. The history of cancer screening. Curr Probl Surg. 2019;56(4):138–163. doi: 10.1067/j.cpsurg.2018.12.006

18. Salmi LR, Coureau G, Bailhache M, Mathoulin-Pélissier S. To screen or not to screen: reconciling individual and population perspectives on screening. Mayo Clin Proc. 2016;91(11):1594–1605. doi: 10.1016/j. mayocp.2016.07.017

19. Samoilov AS, Udalov YuD, Korovkina EP, Dmitrieva LV, Biryukov AP, Trofimenko YuG. [Statistics of malignant neoplasms in the contingent attached to health facilities of the Federal Medical and Biological Agency of Russia, 2012–2016. Zlokachestvennye Opukholi. 2018;8(3S1):279–280. (In Russ.) doi: 10.18027/2224-5057

20. Chervov VO, Artymuk NV. Gynecological cancer awareness in Kemerovo region. Fundamental’naya i Klinicheskaya Meditsina. 2016;1(1):64–68. (In Russ.)

21. Solopova AG, Vlasina AY, Idrisova LE, Moskvichyova VS, Bazhanov SA. Rehabilitation of oncogynecological patients: current problems and possible solutions. Vestnik Vosstanovitel’noy Meditsiny. 2019;(5(93)):87–96. (In Russ.)

22. Radzinskiy VE, Aminodova IP, Kryuchko DS. Screening of tumor diseases of reproductive system: possibilities and prospects. Ul’yanovskiy Mediko-Biologicheskiy Zhurnal. 2018;(3):63–79. (In Russ.) doi: 10.23648/ UMBJ.2018.31.17217

23. Jeffers AM, Sieh W, Lipson JA, et al. Breast cancer risk and mammographic density assessed with semiautomated and fully automated methods and BI-RADS. Radiology. 2017;282(2):348–355. doi: 10.1148/ radiol.2016152062